ArticleFrontiers in toxicology2026
A human liver organoid platform for hepatotoxicity assessment: evaluation using reference compounds.
Article in Frontiers in toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Recent advances in organoid technology have enabled the development of human-relevant models. However, their application in toxicity assessments remains limited. Our previous study employed a liver organoid platform to evaluate drug toxicity and subsequently suggested its utility as a model for toxicity assessment. Building on this, we aimed to assess the exploratory response of the liver organoid model using a panel of selected reference compounds, including substances classified according to the United Nations Globally Harmonized System acute toxicity criteria. Methods: Human liver organoids derived from induced pluripotent stem cells were exposed to a panel of reference compounds, and toxicity responses were evaluated using multiple endpoints, including cell viability assays, functional biomarker measurements, imaging, and transcriptomic analysis. Results: Exposure to the reference compounds resulted in compound-specific changes across multiple endpoints, including cell viability, hepatic functional markers such as albumin secretion, and transcriptomic responses. Transcriptomic analysis further revealed compound-specific changes in gene expression associated with hepatotoxic responses, supporting the observed functional alterations. These findings suggest that liver organoids may capture compound-specific and multi-dimensional toxicity responses, supporting their potential as an Conclusion: Therefore, the present results should be interpreted as an exploratory evaluation of platform performance rather than evidence of predictive capability. Future studies incorporating greater chemical diversity and functional validation are required to assess the broader applicability of this model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.